Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610101 | 0.84 | GAA (0.66) | ALDH1A1GAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL2695730 | 0.81 | ALDH1A1 (0.58) | ALDH1A1GAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL1286082 | 0.81 | GAA (0.62) | ALDH1A1GAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL20824968 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL1812216 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL25094969 | 0.81 | ALDH1A1 (0.67) | ALDH1A1GAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL9329665 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL2695688 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAAMAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL1185619 | 0.80 | GAA (0.66) | ALDH1A1GAAMAPTLMNAHTT | |
| SCHEMBL21065527 | 0.79 | HTT (0.68) | ALDH1A1GAAMAPTHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150198552-A9 | NOVEL CHEMISTRY USED IN BIOSENSORS | OHMX CORPORATION (US) | 2015-07-16 | — | — | US | disclosed |
| US-20140311922-A1 | NOVEL CHEMISTRY USED IN BIOSENSORS | OHMX CORPORATION (US) | 2014-10-23 | — | — | US | disclosed |
| US-8734631-B2 | Chemistry used in biosensors | OHMX CORPORATION (US) | 2014-05-27 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | SCION PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2005087750-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | ALDH1A1 3706/4885GAA 1560/4885MAPT 490/4885 |
| US-20070203194-A1 | Calcium channel modulators comprising 3-thio-4H-1,2,4-triazoles or S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | CACNA1C, CACNA1D, CACNA1G | ALDH1A1 756/4885GAA 2648/4885MAPT 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.